Pharmacist scope of practice, standards of practice, and standards of professional performance for diabetes educators

Diabetes Educator

Volumn 35, Issue SUPPL. 3, 2009, Pages

  Shane McWhorter, Laura ^a   Armor, Becky ^b   Johnson, John T ^c   Letassy, Nancy ^b   Reichert, Shay L ^d   Sisson, Evan M ^e   Hanson, Judith B Sommers ^f   Triplett, Curtis ^g   Vivian, Eva M ^h  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c PRESBYTERIAN COLLEGE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f Walgreen   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71549147579     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721709349590     Document Type: Article

References (66)

1. Martin C., Daly A., Shane-McWhorter L., Shwide-Slavin C., Kushion W. The scope of practice, standards of practice, and standards of professional performance for diabetes educators. Diabetes Educ. 2005;31:487-512.
2. American Nurses Association and American Association of Diabetes Educators. Scope and Standards of Diabetes Nursing Practice. 2nd ed. Washington, DC: American Nurses Association; 2003.
3. Kulkarni K., Boucherl JL, Daly A.,et al.American Dietetic Association: Standards of practice and standards of professional performance for registered dietitians (generalist, specialty, and advanced) in diabetes care. J Am Diet Assoc. 2005;105:819-824.
4. Centers for Disease Control and Prevention. National diabetes fact sheet. http://www.cdc.gov/diabetes/pubs/factsheet05.htm. Accessed June 21, 2008.
5. Duncan GE Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006;160:523-528.
6. American Diabetes Association. Direct and indirect costs of diabetes in the US. 2007. www.diabetes.org/diabetes-statistics/costof-diabetes-in-us.jsp. Accessed June 21, 2008.
7. Report of the Task Force on the Delivery of Diabetes Self-management Education and Medical Nutrition Therapy. Diabetes Spectrum. 1999;12(1).
8. Mensing C., Boucher J., Cypress M.,et al.National standards for diabetes self-management education. Diabetes Care. 2004; 27(suppl 1):S143-S150.
9. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31:S12-S54.
10. Funnell MM, Brown TL, Childs BP,et al:National standards for diabetes self-management education. Diabetes Care. 2007;30: 1630-1637.
11. Kiel PJ, McCord AD Collaborative practice agreement for diabetes management [letter]. Am J Health Syst Pharm. 2006;63:209-210.
12. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention and delay of type 2 diabetes [position statement]. Diabetes Care. 2002;25:742-749.
13. Pan XR, Li GW, Hu YH,et al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
14. Tuomilehto J., Lindstrom J., Eriksson JG,et al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
15. Diabetes Prevention Program Research Group. Reduction in the evidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med. 2002;346:393-403.
16. Buchanan TA, Xiang AH, Peters RK,et al.Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
17. Xiang AH, Peters RK, Kjos SL,et al.The pioglitazone in prevention of diabetes (PIPOD) trial. Diabetes. 2006;55:517-522.
18. Chiasson JL, Josse RG, Gomis R.,et al;for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
19. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
20. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
21. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
22. Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
23. Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290:2159-2167.
24. Martin CL, Albers J., Herman WH,et al;for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340-344.
25. Nathan DM, Cleary PA, Backlund JY,et al;Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
26. Harris MI Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med. 1996;124(1 pt 2):117-122.
27. Kroon LA, Coleman LT, Koda-Kimble MA The management of type 2 diabetes mellitus: a call to action for pharmacists. US Pharm. 1997;(suppl 1):1-18.
28. US Department of Labor, Bureau of Labor Statistics. Earnings [article online] 2004. http://www.bls.gov/oco/ocos079.htm#earnings.
29. Choe MH, Mitrovich S., Dubay D.,et al.Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11(4):253-260.
30. Clifford R., Davis W., Batty K., Davis TME Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care. 2005;4:771-776.
31. Jaber LA, Halapy H., Fernet M., Tummalapalli S., Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30(3):238-243.
32. Leal S., Glover J., Herrier R., Felix A. Improving quality of care in diabetes through a comprehensive pharmacist based disease management program. Diabetes Care. 2004;27(12):2983-2984.
33. Cranor CW Outcomes of the Asheville diabetes project. Pharmacy Times. 1998;(suppl):19-25.
34. Cranor CW, Christensen DB The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003; 43:149-159.
35. Cranor CW, Christensen DB The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003; 43:160-172.
36. Cranor CW, Bunting BA, Christensen DB The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-184.
37. Coast-Senior EA, Kroner BA, Kelley CI, Trilli LE Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636-641.
38. Harris IM, Baker E., Berry TM,et al;for American College of Clinical Pharmacy. Developing a business-practice model for pharmacy services in ambulatory settings. Pharmacotherapy. 2008; 28:7e-34e.
39. Gong C., Hasson NK, Lum BL Impact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Managed Care Pharm. 1999; 5(6):511-515.
40. Cioffi ST, Caron MF, Kalus JS, Hill P., Buckley TE Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004;38(5):771-775.
41. Carmichael JM, Alvarez A., Chaput R., DiMaggio J., Magallon H., Mambourg S. Establishment and outcomes of a model primary care pharmacy service system. Am J Health Syst Pharm. 2004; 61(5):472-482.
42. Felt-Lisk S., Mays G., Harris L., Lee M., Nyman R., Smieliauskas F. Evaluation of HRSA's clinical pharmacy demonstration projects. Final report. November 30, 2004. MPR reference no 8928-500. http://www.mathematica-mpr.com/publications/PDFs/evalhrsavol1.pdf. Accessed June 21, 2008.
43. Shane-McWhorter L., Oderda GM Providing diabetes education and care to underserved patients in a collaborative practice at a Utah community health center. Pharmacotherapy. 2005;25(1):96-109.
44. Glenn ZM, Simmons ML, West CP, Schmidt AM Advantages of a pharmacist-led diabetes education program. US Pharm. 2005;11:52-61.
45. Yanchick JK Implementation of a drug therapy monitoring clinic in a primary-care setting. Am J Health Syst Pharm. 2000;57(suppl 4):S30-S34.
46. Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health-Syst Pharm. 2006;63:1325-1331.
47. Gerber RA, Liu G., McCombs JS Impact of pharmacist consultations provided to patients with diabetes on healthcare costs in a health maintenance organization. Am J Manag Care. 1998;4(7): 991-1000.
48. McConnell KJ, Humphries TL, Raebel MA, Merenich JA Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Pharmacotherapy. 2003;23(12):1564-1572.
49. McCord AD Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy. 2006; 26:248-253.
50. Nicholas A., Divine H., Nowak-Rapp M., Roberts KB University and college of pharmacy collaboration to control health plan prescription drug costs. J Am Pharm Assoc. 2007;47:86-92.
51. Letassy NA, Armor BL, Britton ML, Farmer KC Pharmacist-managed diabetes service in a family medicine practice improves patient outcomes. Drug Benefit Trends. 2003; 15(suppl H):21-32.
52. Ragucci KR, Fermo JD, Wessell AM, Chumney EC Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy. 2005;25(12): 1809-1816.
53. Rothman RL, Malone R., Bryant B.,et al.A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes Am J Med. 2005;118(3):276-284.
54. Nowak SN, Singh R., Clarke A., Campbell E., Jaber LA Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic. Diabetes Care. 2002;25(8):1479.
55. Kiel PJ, McCord AD Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39:1828-1832.
56. Kelly C., Rodgers PT Implementation and evaluation of a pharmacist managed diabetes service. J Managed Care Pharm. 2000;6(6):488-493.
57. Stroup J., Kane MP, Busch RS, Bakst G., Hamilton RA The diabetes home visitation program. Am J Pharm Educ. 2003;67(3):1-8.
58. Jensen B. One year's experience. The Lakeshore Diabetes Project: from Asheville to Wisconsin. Journal of the Pharmacy Society of Wisconsin. 2004;November/December:22-23.
59. Garrett DG, Bluml BM Patient self-management program for diabetes: first year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005; 45:130-137.
60. Baran RW, Crumlish K., Patterson H.,et al.Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health Syst Pharm. 1999;56(15):1535-1539.
61. Hogue VW, Babamoto KS, Jackson TB, Cohen LB, Laitinen DL Pooled results of community pharmacy-based diabetes education programs in underserved communities. Diabetes Spectrum. 2003;16(2):129-133.
62. West D., Blevins MA, Brech D., Stotts F., Gardner S. A multidisciplinary approach in a community pharmacy can improve outcomes for diabetes patients. Diabetes Educ. 2003; 29(6):962-968.
63. Nau DP, Blevins JD, Neal SE Collaborating with community pharmacists to improve the quality of diabetes care in an IPAmodel HMO. J Manag Care Pharm. 2001;7:292-296.
64. Nau DP, Ponte CD Effects of a community pharmacist-based diabetes patient management program on intermediate clinical outcome measures. J Manag Care Pharm. 2002;8(1):48-53.
65. Munroe WP, Kunz K., Dalmady-Israel C., Potter L., Schonfeld WH Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther. 1997;19(1): 113-123.
66. Wubben DP, Vivian EM Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008; 28:421-436.